# From Sequence Design to AOC Production: Medicilon's End-to-End RNAi Development Platform

Aouang[1], Lei Lian[1], Maosheng Du[1], Binan[1], Hengyu Long[1], Yingcong Lin[1], and Steven Chang[1]
[1] Shanghai Medicilon Inc., Chuanda Road, Shanghai 01, China [1] Medicilon SA Corp., 0 Maguire Road, Suite 103, Lexington, MA 01, USA

Anchored by a sophisticated RNAi platform, our AOC capabilities are supported by advanced conjugation chemistries and high-resolution analytical methods, and enabled by integrated expertise spanning sequence design, nucleotide synthesis, and in vivo evaluation, together providing a rigorous framework for regeneration oligonucleotide therapeutics

## Medicilon Optimal Design (MOD)

## Mono-Nucleotide Synthesis

## Delivery & Carrier Synthesis